Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7943MR)

This product GTTS-WQ7943MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7943MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6805MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ13470MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ9664MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ15123MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ14677MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ4595MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ8219MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ1060MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW